The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
Abstract
Purpose: Uncertain short‐ and long‐term cancer risks with anti‐TNF therapies is a concern, and led to a recent black box warning. This meta‐analysis, requested by the European Medicines Agency, aimed at better assessing short‐term risks by using meta‐analytic techniques based on individual patient data from all corporate‐sponsored randomized controlled trials (RCTs) of adalimumab, etanercept, and infliximab. Methods: All 74 RCTs of TNF inhibitors of at least 4 weeks duration were provided to independent investigators, including case narratives for events occurring between trial start until 30 days after planned end of treatment and indicating a possible cancer. Relative risks were estimated using Bayesian piecewise exponential models. Results: One hundred thirty (0.84%) of 15 418 individuals randomized to anti‐TNF therapy were diagnosed with cancer, compared to 48 (0.64%) of 7486 individuals randomized to comparators. The relative risks associated with all anti‐TNF were 0.99 (95%CI 0.61–1.68) for cancers excluding non‐melanoma skin cancer (NMSC), and 2.02 (95%CI 1.11–3.95) for NMSC. There were indications of differences in the relative risks for the three anti‐TNF drugs, but also of differences across the cancer rates in the three comparator arms for adalimumab, etanercept, and infliximab. Conclusions: Despite a reassuring overall short‐term risk, we could neither refute nor verify that individual anti‐TNF therapies affect the short‐term clinical emergence of cancer. Despite representing the best available evidence, statistical precision, and differences in baseline cancer risk and reporting detail between trials of adilumumab, etanercept, and infliximab hampered distinction of drug‐specific from trial effects, illustrating the challenges in safety‐assessments using RCT meta‐analyses. Long‐term risk assessment requires observational studies. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
TNF-α in promotion and progression of cancer
Balkwill, F. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9005-3 · Cited by 915
Etanercept plus Standard Therapy for Wegener's Granulomatosis
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa041884 · Cited by 834
TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility
van Horssen, R., ten Hagen, T. L. M., & Eggermont, A. M. M. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-397 · Cited by 701
Peyrin–Biroulet, L., Deltenre, P., de Suray, N., Branche, J., Sandborn, W. J., & Colombel, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.014 · Cited by 577
Wolfe, F., & Michaud, K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22864 · Cited by 534
Geborek, P., Bladström, A., Turesson, C., Gulfe, A., Petersson, I. F., Saxne, T., Olsson, H., & Jacobsson, L. T. H. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030528 · Cited by 427
Askling, J., Fored, C. M., Baecklund, E., Brandt, L., Backlin, C., Ekbom, A., Sundström, C., Bertilsson, L., Cöster, L., Geborek, P., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.033241 · Cited by 417
Self-citationRheumatoid arthritis and cancer risk
Mellemkjær, L., Linet, M. S., Gridley, G., Frisch, M., Møller, H., & Olsen, J. H. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00210-9 · Cited by 383
Askling, J., Fored, C. M., Brandt, L., Baecklund, E., Bertilsson, L., Feltelius, N., Cöster, L., Geborek, P., Jacobsson, L. T., Lindblad, S., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.033993 · Cited by 377
Self-citation
Cited by
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
ACG clinical guideline: Preventive care in inflammatory bowel disease
Farraye, F. A., Melmed, G. Y., Lichtenstein, G. R., & Kane, S. V. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.537 · Cited by 473
Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., Gabrielli, E. M., Lonati, A. C., Moja, L., Cinquini, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1240783 · Cited by 308
Lopez-Olivo, M. A., Tayar, J. H., Martinez-Lopez, J. A., Pollono, E. N., Cueto, J. P., Gonzales-Crespo, M. R., Fulton, S., & Suarez-Almazor, M. E. (2012) · JAMA · doi:10.1001/2012.jama.10857 · Cited by 295
Monti, S., Grosso, V., Todoerti, M., & Caporali, R. (2018) · Rheumatology · doi:10.1093/rheumatology/key109 · Cited by 170
Metadata
- Authors
- Askling, J., Fahrbach, K., Nordstrom, B., Ross, S., Schmid, C. H., & Symmons, D.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2010-12-07
- Volume
- 20
- Issue
- 2
- Pages
- 119-130
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W1986109277
- Cited by
- 301
- References
- 15
- FWCI
- 13.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. https://app.cochat.ai/papers/10.1002/pds.2046
- The paper
- Askling, J., Fahrbach, K., Nordstrom, B., Ross, S., Schmid, C. H., & Symmons, D. (2011). Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.2046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
